Serum cytokine levels in psoriasis vulgaris

British Journal of Biomedical Science

Volumn 58, Issue 1, 2001, Pages 40-44

  El Barnawi, N Y ^a   Giasuddin, A S M ^a,b   Ziu, M M ^a   Singh, M ^a  

^a AL ARAB MEDICAL UNIVERSITY   (Libyan Arab Jamahiriya)

^b NONE   (Libyan Arab Jamahiriya)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FLUMETASONE PIVALATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KERATINOCYTE; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; SCORING SYSTEM;

ACUTE DISEASE; ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-2; INTERLEUKIN-4; MALE; MIDDLE AGED; PSORIASIS;

EID: 0035076802     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mackie RM. Clinical dermatology: an illustrated textbook (2nd edn.) Oxford: Oxford University Press, 1986: 35-7.
2. Camp RDR. Psoriasis. In: RH Champion, JL Burton, FJG Ebling, eds. Textbook of dermatology, 5th edn. Oxford: Blackwell Scientific Publications, 1992: 1391-457.
3. Fry L. Psoriasis. Br J Dermatol 1988; 119: 445-61.
4. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992; 126:1-9.
5. Valdimarsson H, Baker BS, Jonsdottir I, Fry L. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986; 7: 256-9.
6. Valdimarsson H, Baker BS, Jonsdottir I et al. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens. Immunol Today 1995; 16: 145-9.
7. Bos JD, DeRie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40-6.
8. Nakamura M, Saito H, Kasanuki J et al. Cytokine production in patients with inflammatory bowel disease. Gut 1992; 33: 933-7.
9. Bjerke JR, Livden JK, Serge M, Mabe R. Interferon in suction blister fluid from psoriatic lesions. Br J Dermatol 1983; 108: 295-8.
10. Camp RD, Fincham NJ, Cunningham FM, Greaves MW, Morris J, Chu A. Psoriatic skin lesions contain biologically active amounts of an interleukin-1-like compound. J Immunol 1986; 137: 3469-3474.
11. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991; 127: 871-84.
12. Gomi T, Shiohara T, Munakata T et al. Interleukin-1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis. Arch Dermatol 1991; 127: 827-30.
13. Shiohara T, Imanishi K, Sagawa Y, Nagashima M. Differential effects of cyclosporine and etretinate on serum cytokine levels in patients with psoriasis. J Am Acad Dermatol 1992; 27: 568-74.
14. LeRoy F, Brown KA, Greaves MW et al. Blood mononuclear cells from patients with psoriasis exhibit an enhanced adherence to cultured vascular endothelium. J Invest Dermatol 1991; 97:511-6.
15. Kupper TS. Interleukin-1 and other immunologically active keratinocyte cytokines: molecular and functional characterisation. Adv Dermatol 1983; 3: 293-305.
16. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
17. Van de Kerkhof PCM. On the limitations of the psoriasis area and severity index (PASI). Br J Dermatol 1992; 126: 205.
18. Kirkwood BM. Essentials of medical statistics. Oxford: Blackwell Scientific Publications,1989.
19. Konnikov N, Pincus SH, Dinarello CA. Elevated plasma interleukin-1 levels in humans following ultraviolet therapy in psoriasis. J Invest Dermatol 1989; 92; 235-9.
20. Ristow HJ. A major factor contributing to epidermal proliferation in inflammatory skin disease appears to be interleukin-1 or a related protein. Proc Natl Acad Sci USA 1987; 84: 1940-4.
21. Larrick JW, Native interleukin-1 inhibitors. Immunol Today, 1989; 10: 61-6.
22. Haskill S, Martin M, Van Lel et al. cDNA cloning of an intracellular form of the human interleukin-1 receptor antagonist associated with endothelium. Proc Natl Acad Sci USA 1991; 88: 3681-5.
23. Scheynius A, Fransson J, Johansson C et al. Expression of interferon-gamma receptors in normal and psoriatic skin. J Invest Dermatol 1992; 98: 255-8.
24. Wahl SM, Hunt DA, Wong HL. Transforming growth factor-β is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 1988; 140: 3026-32.
25. Tapper RI. The anti-tumor and pro-inflammatory actions of IL-4. Res Immunol 1993; 144: 633-7.
26. Thornhill MH, Huskard DO. IL-4 regulates endothelial cell activation by IL-11, tumor necrosis factors or interferon-gamma. J Immunol 1990; 145: 865-72.
27. Pretolani M, Goldman M, IL-10: a potential therapy for allergic inflammation? Immunol Today 1997; 18: 277-80.
28. Sosroseno W, Herminajeng E. The immunoregulatory role of transforming growth factor beta. Br J Biomed Sci 1995; 52: 142-8.
29. Strober W, Kelsall B, Fuss I et al. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today 1997; 18: 61-4.